Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Change in Receivables (2022 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Change in Receivables for 4 consecutive years, with -$6.2 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables fell 677.71% to -$6.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.6 million through Dec 2025, up 107.68% year-over-year, with the annual reading at $7.6 million for FY2025, 107.68% up from the prior year.
  • Change in Receivables for Q4 2025 was -$6.2 million at Rhythm Pharmaceuticals, down from $6.6 million in the prior quarter.
  • The five-year high for Change in Receivables was $7.8 million in Q2 2025, with the low at -$6.2 million in Q4 2025.
  • Average Change in Receivables over 4 years is $1.7 million, with a median of $1.2 million recorded in 2023.
  • Peak annual rise in Change in Receivables hit 286.42% in 2025, while the deepest fall reached 677.71% in 2025.
  • Over 4 years, Change in Receivables stood at $2.9 million in 2022, then plummeted by 88.74% to $326000.0 in 2023, then tumbled by 343.56% to -$794000.0 in 2024, then crashed by 677.71% to -$6.2 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$6.2 million, $6.6 million, and $7.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.